EP. 3: The Rationale for Immunotherapy in R/M NPC
June 19th 2025
Panelists discuss the biological rationale and consistent clinical data supporting PD-1 checkpoint inhibitors—such as toripalimab, nivolumab, and pembrolizumab—as active and meaningful treatments in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), particularly given the Epstein-Barr virus (EBV)-driven, immune-infiltrated nature of the disease.